Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1537397 | 0.98 | CYP2D6 (0.63) | CYP2D6MAPK1IDO1NOS1NOS2 | |
| Bromide SCHEMBL4919111 | 0.79 | CYP2D6 (0.43) | CYP2D6MAPK1IDO1NOS1NOS2 | |
| SCHEMBL13962802 | 0.78 | CYP2D6 (0.45) | CYP2D6MAPK1IDO1NOS1NOS2 | |
| SCHEMBL11954746 | 0.77 | IDO1 (0.47) | CYP2D6MAPK1IDO1NOS1NOS2 | |
| SCHEMBL21473764 | 0.77 | CYP2D6 (0.44) | CYP2D6MAPK1IDO1NOS1NOS2 | |
| SCHEMBL12774630 | 0.76 | CYP2D6 (0.42) | CYP2D6MAPK1NOS2CYP1A2CYP3A4 | |
| SCHEMBL15457409 | 0.76 | CYP2D6 (0.46) | CYP2D6MAPK1NOS2CYP1A2CYP3A4 | |
| SCHEMBL14047849 | 0.75 | CYP2D6 (0.43) | CYP2D6MAPK1NOS2NOS3CYP1A2 | |
| Bromide SCHEMBL4917874 | 0.75 | MAPK1 (0.47) | CYP2D6MAPK1IDO1NOS1NOS2 | |
| SCHEMBL27566075 | 0.74 | CYP2D6 (0.41) | CYP2D6MAPK1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3553053-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | Red Bull GmbH (AT) | 2019-10-16 | — | — | EP | disclosed |
| EP-1506171-B1 | PREPARATIONS OF A SULFINYL ACETAMIDE | CEPHALON INC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7057069-B2 | production of modafinil by reacting benzhydrol, thiourea and hydrobromic acid with a base potassium carbonate salt, then hydrolyzing with poatssium hydroxide and chloroacetamide; useful in treatment of narcolepsy and other sleep disorders; commercial scale | CEPHALON, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20050171209-A1 | Preparations of a sulfinyl acetamide | CEPHALON, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-6875893-B2 | Preparations of a sulfinyl acetamide | CEPHALON, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1506171-A1 | PREPARATIONS OF A SULFINYL ACETAMIDE | CEPHALON, INC. (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040002547-A1 | Preparations of a sulfinyl acetamide | CEPHALON LLC | 2004-01-01 | — | — | US | disclosed |
| WO-2003099774-A1 | PREPARATIONS OF A SULFINYL ACETAMIDE | CEPHALON, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002547-A1 | Preparations of a sulfinyl acetamide | SULT2A1, SULT1A1, AADAC | SLC6A4 176/4885SLC6A3 45/4885CYP2D6 153/4885 |
| US-20050171209-A1 | Preparations of a sulfinyl acetamide | SULT2A1, SULT1A1, AADAC | SLC6A4 176/4885SLC6A3 45/4885CYP2D6 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.